Odysight.ai® Receives Purchase Order from Honeywell Aerospace APU Division to Launch Proof of Concept of Odysight.ai’s Advanced Predictive Maintenance Vision-Based Monitoring System on Honeywell Aerospace Auxiliary Power Units Portfolio

Ramat Gan, Israel, June 18, 2026 (GLOBE NEWSWIRE) — Odysight.ai® (NASDAQ/TASE: ODYS) today announced the receipt of a purchase order from Honeywell Aerospace APU Division for a proof-of-concept (PoC) collaboration to evaluate Odysight.ai’s visual sensing platform across Honeywell Aerospace Auxiliary Power Units (APU) portfolio.

Ophthalmic Clinical Trials Market Size to Reach USD 3.30 Billion by 2035 as Gene Therapy and Retinal Disease Drug Development Accelerate – SNS Insider

The U.S. Ophthalmic Clinical Trials Market was valued at USD 0.66 Billion in 2025 and is projected to reach USD 1.25 Billion by 2035, while Europe is expected to grow from USD 0.49 Billion to USD 0.89 Billion during the forecast period, driven by expanding retinal disease pipelines and ophthalmic innovation.

The U.S. Ophthalmic Clinical Trials Market was valued at USD 0.66 Billion in 2025 and is projected to reach USD 1.25 Billion by 2035, while Europe is expected to grow from USD 0.49 Billion to USD 0.89 Billion during the forecast period, driven by expanding retinal disease pipelines and ophthalmic innovation.

Ophthalmic Clinical Trials Market Size to Reach USD 3.30 Billion by 2035 as Gene Therapy and Retinal Disease Drug Development Accelerate – SNS Insider

The U.S. Ophthalmic Clinical Trials Market was valued at USD 0.66 Billion in 2025 and is projected to reach USD 1.25 Billion by 2035, while Europe is expected to grow from USD 0.49 Billion to USD 0.89 Billion during the forecast period, driven by expanding retinal disease pipelines and ophthalmic innovation.

The U.S. Ophthalmic Clinical Trials Market was valued at USD 0.66 Billion in 2025 and is projected to reach USD 1.25 Billion by 2035, while Europe is expected to grow from USD 0.49 Billion to USD 0.89 Billion during the forecast period, driven by expanding retinal disease pipelines and ophthalmic innovation.

Odysight.ai® Receives Purchase Order from Honeywell Aerospace APU Division to Launch Proof of Concept of Odysight.ai’s Advanced Predictive Maintenance Vision-Based Monitoring System on Honeywell Aerospace Auxiliary Power Units Portfolio

Ramat Gan, Israel, June 18, 2026 (GLOBE NEWSWIRE) — Odysight.ai® (NASDAQ/TASE: ODYS) today announced the receipt of a purchase order from Honeywell Aerospace APU Division for a proof-of-concept (PoC) collaboration to evaluate Odysight.ai’s visual sensing platform across Honeywell Aerospace Auxiliary Power Units (APU) portfolio.

Triller Group Inc. Announces Share Consolidation

Los Angeles, June 18, 2026 (GLOBE NEWSWIRE) — Triller Group Inc. (Nasdaq: ILLR / ILLRW) (the “Company” or “Triller”) today announced that it will effect a share consolidation of its common stock, par value $0.001 per share (the “Common Stock”) at a ratio of 1-for-10, effective on June 23, 2026 (the “Share Consolidation”). The Company’s Common Stock are expected to begin trading on a post-consolidation basis at the open of the market session on June 23, 2026. Upon the market opening on June 23, 2026, the Company’s Common Stock will continue to be traded on The Nasdaq Stock Market under the symbol “ILLR” with the new CUSIP number 895970309.

Preclinical Imaging Market Size to Reach USD 7.24 Billion by 2035 as Pharmaceutical R&D and Drug Discovery Investments Accelerate – SNS Insider

The U.S. Preclinical Imaging Market was valued at USD 1.12 Billion in 2025 and is projected to reach USD 1.85 Billion by 2035, while Europe is expected to grow from USD 1.28 Billion to USD 1.95 Billion, driven by expanding pharmaceutical research, imaging biomarker adoption, and advanced preclinical research infrastructure.

The U.S. Preclinical Imaging Market was valued at USD 1.12 Billion in 2025 and is projected to reach USD 1.85 Billion by 2035, while Europe is expected to grow from USD 1.28 Billion to USD 1.95 Billion, driven by expanding pharmaceutical research, imaging biomarker adoption, and advanced preclinical research infrastructure.

Nightfood Holdings Inc. (OTCQB: NGTF) Builds AI-Driven Automation Tools for Hospitality, Pharmaceutical, Lab and Industrial Spaces

NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) — via AINewsWireNightfood Holdings Inc. (OTCQB: NGTF) today announces its placement in an editorial published by AINewsWire (“AINW”), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) — Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC informing the Company that, as of June 17, 2026, it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). Silo’s common stock continues to trade on the Nasdaq Capital Market, and the matter is now closed.

Meet Your Cosmic Crushes with New Refreshing Summer Drinks Available Today at Scooter’s Coffee®

Scooter’s Coffee today launched limited-time flavors in collaboration with Little Debbie®, a new Bombshell lineup featuring strawberry and dragon fruit flavors, and a new trio of delicious Dirty Sodas.

Scooter's Coffee today launched limited-time flavors in collaboration with Little Debbie®, a new Bombshell lineup featuring strawberry and dragon fruit flavors, and a new trio of delicious Dirty Sodas.